Calamos Advisors’s Neuropace NPCE Stock Holding History

Calamos Advisors’s Portfolio NPCE Stock Details NPCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-11,083	Closed	-$136K	–	968
2025 Q1	$136K	Buy	+11,083	New	+$139K	﹤0.01%	816

Other funds holding NPCE

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

KLP

Kent Lake PR Anasco, Puerto Rico $198M AUM 5.21% 1-Year Est. Return

Calamos Advisors's NPCE Position: Q2 2025 in Review

Calamos Advisors sold out of Neuropace (NPCE) in Q2 2025, closing a stake of 11,083 shares — an estimated $136K sold.

Calamos Advisors first reported a position in NPCE in Q1 2025 and held it in 1 quarter. The position peaked at $136K in Q1 2025. 98 funds tracked by Wall St. Rank hold NPCE as of Q2 2025.

Calamos Advisors reported no remaining Neuropace position as of Q2 2025 after selling out during the quarter.
Calamos Advisors sold 11,083 Neuropace shares in Q2 2025, an estimated $136K.
Calamos Advisors first reported a position in Neuropace in Q1 2025 and held it in 1 quarter.
Calamos Advisors's Neuropace position peaked at $136K in Q1 2025.
98 funds tracked by Wall St. Rank held Neuropace as of Q2 2025.

Based on Calamos Advisors's 13F filing for Q2 2025, filed 8 Aug 2025.